NYSE:GSK - GlaxoSmithKline Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 13
  • Breakdown:
  • 2 Sell Ratings
  • 5 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$39.06
▼ -0.16 (-0.41%)

This chart shows the closing price for GSK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GlaxoSmithKline Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GSK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GSK

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 13 analysts offering 12 month price targets for GlaxoSmithKline in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $39.06.

This chart shows the closing price for GSK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 13 investment analysts is to hold stock in GlaxoSmithKline. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 2 sell ratings
3/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings
6/22/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 2 sell ratings
9/20/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 3 sell ratings
12/19/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 2 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 2 sell ratings
6/17/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 2 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 2 sell ratings
9/15/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 5 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/26/2021UBS GroupReiterated RatingNeutralLow
8/20/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
8/19/2021Berenberg BankReiterated RatingBuyLow
8/3/2021UBS GroupReiterated RatingNeutralLow
7/19/2021BarclaysReiterated RatingUnderweightMedium
7/6/2021Morgan StanleyReiterated RatingEqual WeightLow
7/1/2021UBS GroupReiterated RatingNeutralLow
6/24/2021Credit Suisse GroupReiterated RatingUnderperformLow
6/23/2021Deutsche Bank AktiengesellschaftUpgradeSell ➝ HoldLow
6/11/2021Deutsche Bank AktiengesellschaftReiterated RatingSellLow
6/2/2021Baader BankReiterated RatingBuyLow
5/11/2021UBS GroupReiterated RatingNeutralLow
4/30/2021Deutsche Bank AktiengesellschaftReiterated RatingSellLow
4/20/2021Morgan StanleyReiterated RatingEqual WeightLow
4/20/2021UBS GroupReiterated RatingNeutralLow
3/29/2021SVB LeerinkReiterated RatingOutperform ➝ Market PerformN/A
3/23/2021SVB LeerinkDowngradeOutperform ➝ Market PerformLow
2/12/2021Morgan StanleyReiterated RatingEqual WeightLow
2/11/2021Berenberg BankReiterated RatingBuyLow
2/9/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
2/8/2021UBS GroupReiterated RatingNeutralLow
2/5/2021BarclaysReiterated RatingUnderweightLow
2/3/2021Deutsche Bank AktiengesellschaftDowngradeHold ➝ SellLow
1/20/2021UBS GroupReiterated RatingNeutralLow
1/20/2021Credit Suisse GroupDowngradeNeutral ➝ UnderperformLow
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageHoldLow
12/16/2020DZ BankReiterated RatingBuyLow
12/8/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
12/3/2020UBS GroupDowngradeBuy ➝ NeutralLow
11/13/2020Morgan StanleyUpgradeUnderweight ➝ Equal WeightLow
11/2/2020Liberum CapitalUpgradeHold ➝ BuyLow
10/30/2020BarclaysReiterated RatingUnderweightLow
10/21/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/12/2020UBS GroupReiterated RatingBuyLow
10/9/2020Morgan StanleyReiterated RatingUnderweightLow
10/5/2020Credit Suisse GroupReiterated RatingNeutralLow
9/29/2020Berenberg BankInitiated CoverageBuyLow
9/23/2020Oddo BhfUpgradeNeutral ➝ BuyMedium
9/18/2020Societe GeneraleReiterated RatingBuyLow
9/8/2020JPMorgan Chase & Co.Reiterated RatingNeutralMedium
9/1/2020AlphaValueUpgradeBuyMedium
9/1/2020Morgan StanleyReiterated RatingUnderweightMedium
8/12/2020UBS GroupReiterated RatingBuyLow
5/14/2020UBS GroupReiterated RatingBuyLow
5/5/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
4/30/2020BarclaysReiterated RatingUnderweightLow
2/12/2020Shore CapitalDowngradeHold ➝ SellLow
1/16/2020BarclaysDowngradeEqual Weight ➝ UnderweightLow
12/2/2019SVB LeerinkInitiated CoverageOutperformLow
11/27/2019UBS GroupUpgradeNeutral ➝ BuyN/A
11/21/2019UBS GroupUpgradeNeutral ➝ BuyLow
10/16/2019New Street ResearchUpgradeReduce ➝ HoldLow
10/11/2019Cantor FitzgeraldUpgradeHold ➝ BuyMedium
9/3/2019Societe GeneraleUpgradeSell ➝ BuyLow
8/29/2019Jefferies Financial GroupReiterated RatingBuyLow
8/13/2019JPMorgan Chase & Co.Reiterated RatingNeutral ➝ NeutralLow
6/17/2019Morgan StanleyReiterated RatingUnderweight ➝ UnderweightLow
6/10/2019CowenReiterated RatingHold$45.00Low
3/8/2019Shore CapitalDowngradeBuy ➝ HoldLow
2/22/2019UBS GroupDowngradeBuy ➝ NeutralLow
1/14/2019Exane BNP ParibasDowngradeOutperform ➝ NeutralMedium
1/14/2019BNP ParibasDowngradeOutperform ➝ NeutralMedium
12/14/2018Morgan StanleyInitiated CoverageUnderweightLow
12/13/2018SunTrust BanksInitiated CoverageHold$38.00Low
12/11/2018Jefferies Financial GroupReiterated RatingBuy ➝ Buy$45.00Low
12/6/2018BarclaysReiterated RatingOverweight ➝ Equal WeightMedium
12/4/2018CfraReiterated RatingHoldMedium
12/4/2018BarclaysDowngradeOverweight ➝ Equal Weight$36.95Low
12/3/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/29/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/23/2018Wolfe ResearchInitiated CoverageMarket PerformMedium
10/10/2018The Goldman Sachs GroupReiterated RatingBuyLow
10/8/2018GuggenheimInitiated CoverageNeutral ➝ NeutralLow
9/25/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
8/30/2018Liberum CapitalDowngradeBuy ➝ HoldLow
8/20/2018ArgusBoost Price TargetBuy ➝ Buy$45.00 ➝ $47.00Low
8/1/2018Deutsche Bank AktiengesellschaftReiterated RatingNeutralLow
7/27/2018Shore CapitalUpgradeHold ➝ BuyLow
7/25/2018Bank of AmericaSet Price TargetHold$40.00Medium
7/20/2018JPMorgan Chase & Co.Reiterated RatingNeutralHigh
6/14/2018DZ BankReiterated RatingBuyLow
4/9/2018Deutsche Bank AktiengesellschaftReiterated RatingNeutralLow
4/4/2018BNP ParibasUpgradeNeutral ➝ OutperformMedium
3/28/2018Deutsche Bank AktiengesellschaftReiterated RatingNeutralMedium
3/22/2018Morgan StanleyUpgradeUnderweight ➝ Equal WeightMedium
2/15/2018CowenReiterated RatingHold$40.00Low
2/9/2018Kepler Capital MarketsUpgradeReduce ➝ HoldLow
2/5/2018JPMorgan Chase & Co.Reiterated RatingNeutralHigh
1/29/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
1/16/2018BarclaysUpgradeEqual Weight ➝ OverweightLow
1/15/2018UBS GroupReiterated RatingBuyMedium
1/11/2018JPMorgan Chase & Co.Reiterated RatingNeutralLow
12/11/2017CowenSet Price TargetHold$38.00Low
11/30/2017ArgusLower Price TargetBuy$40.00Low
11/27/2017UBS GroupUpgradeNeutral ➝ Buy$35.04 ➝ $35.85Low
11/6/2017InvestecDowngradeBuy ➝ HoldN/A
10/26/2017Bank of AmericaDowngradeBuy ➝ NeutralN/A
10/24/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
10/18/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
9/21/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
9/14/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
9/8/2017Morgan StanleyDowngradeEqual Weight ➝ UnderweightLow
8/31/2017ArgusReiterated RatingBuy$50.00Low
7/27/2017CitigroupReiterated RatingNeutralLow
7/24/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
7/13/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
7/5/2017CitigroupDowngradeBuy ➝ NeutralMedium
6/16/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
5/31/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
5/26/2017Berenberg BankUpgradeHold ➝ BuyLow
4/25/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
4/6/2017BNP ParibasLower Price Target$37.00Low
4/5/2017Exane BNP ParibasUpgradeUnderperform ➝ NeutralLow
4/5/2017BNP ParibasUpgradeUnderperform ➝ Neutral$45.58 ➝ $37.20Low
4/5/2017JPMorgan Chase & Co.Reiterated RatingNeutralLow
3/9/2017Liberum CapitalInitiated CoverageBuy ➝ BuyLow
3/9/2017Kepler Capital MarketsInitiated CoverageReduce ➝ ReduceLow
3/7/2017BarclaysInitiated CoverageEqual WeightN/A
2/19/2017Jefferies Financial GroupReiterated RatingBuyN/A
2/15/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
2/9/2017Deutsche Bank AktiengesellschaftReiterated RatingNeutralN/A
2/7/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
1/30/2017JPMorgan Chase & Co.Reiterated RatingNeutralN/A
12/27/2016The Goldman Sachs GroupReiterated RatingBuyN/A
12/21/2016The Goldman Sachs GroupReiterated RatingBuyN/A
12/20/2016Jefferies Financial GroupReiterated RatingBuyN/A
12/1/2016The Goldman Sachs GroupReiterated RatingBuyN/A
11/7/2016CitigroupReiterated RatingBuyN/A
10/27/2016Deutsche Bank AktiengesellschaftReiterated RatingHoldN/A
10/26/2016Beaufort SecuritiesReiterated RatingBuyN/A
10/25/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
10/20/2016InvestecInitiated CoverageBuyN/A
10/19/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
9/23/2016CitigroupReiterated RatingBuyN/A
9/23/2016Piper Jaffray CompaniesInitiated CoverageOverweightN/A
9/22/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
9/20/2016Bank of AmericaReiterated RatingBuy$50.00N/A
9/16/2016Beaufort SecuritiesReiterated RatingBuyN/A
9/16/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
(Data available from 9/16/2016 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 25 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
2/18/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/20/2021
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/19/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/18/2021
  • 7 very positive mentions
  • 10 positive mentions
  • 6 negative mentions
  • 4 very negative mentions
7/18/2021
  • 5 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/17/2021
  • 2 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/16/2021

Current Sentiment

  • 2 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
GlaxoSmithKline logo
GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Read More

Today's Range

Now: $39.06
Low: $38.80
High: $39.14

50 Day Range

MA: $40.53
Low: $39.02
High: $42.33

52 Week Range

Now: $39.06
Low: $33.26
High: $42.68

Volume

98,941 shs

Average Volume

4,857,304 shs

Market Capitalization

$105.17 billion

P/E Ratio

16.48

Dividend Yield

5.31%

Beta

0.7

Frequently Asked Questions

What sell-side analysts currently cover shares of GlaxoSmithKline?

The following Wall Street sell-side analysts have issued reports on GlaxoSmithKline in the last twelve months: Baader Bank, Barclays PLC, Berenberg Bank, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, DZ Bank AG, JPMorgan Chase & Co., Liberum Capital, Morgan Stanley, Oddo Bhf, Societe Generale, SVB Leerink LLC, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for GSK.

What is the current price target for GlaxoSmithKline?

0 Wall Street analysts have set twelve-month price targets for GlaxoSmithKline in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for GlaxoSmithKline in the next year.
View the latest price targets for GSK.

What is the current consensus analyst rating for GlaxoSmithKline?

GlaxoSmithKline currently has 2 sell ratings, 5 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GSK, but not buy more shares or sell existing shares.
View the latest ratings for GSK.

What other companies compete with GlaxoSmithKline?

How do I contact GlaxoSmithKline's investor relations team?

GlaxoSmithKline's physical mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The pharmaceutical company's listed phone number is 442080475000 and its investor relations email address is [email protected] The official website for GlaxoSmithKline is www.gsk.com.